Pulmonary Department, Hospital Álvaro Cunqueiro, Vigo Health Area; NeumoVigoI+i Research Group, Vigo Biomedical Research Institute (IBIV), Vigo, Spain.
University of Santiago de Compostela, Preventive Medicine and Public Health. School of Medicine, San Francisco st s/n Santiago de Compostela, A Coruña, Spain.
Respir Res. 2019 Aug 28;20(1):198. doi: 10.1186/s12931-019-1155-2.
There is a relationship between Chronic Obstructive Pulmonary Disease (COPD) and the development of lung cancer (LC). The aim of this study is to analyse several blood markers and compare their concentrations in patients with only COPD and LC + COPD.
Case-control study with cases presenting combined LC and COPD and two control groups (patients presenting only COPD and patients presenting only LC). We also included LC patients with descriptive purposes. In both groups, peripheral blood analyses of TNF-α, IL-6, IL-8, total leukocyte, lymphocyte and neutrophil counts, neutrophil-to-lymphocyte ratio, total platelet count, mean platelet volume, platelet-to-lymphocyte ratio, alpha 1-antitripsin (A1AT), IgE, C-reactive protein, fibrinogen, cholesterol and bilirubin were performed. We developed univariate and multivariate analyses of these markers, as well as a risk score variable, and we evaluated its performance through ROC curves.
We included 280 patients, 109 cases (LC + COPD), 83 controls (COPD) and 88 LC without COPD. No differences were observed in the distribution by sex, age, BMI, smoking, occupational exposure, lung function, GOLD stage or comorbidity. Patients with LC + COPD had significantly higher levels of neutrophils [OR 1.00 (95%CI 1.00-1.00), p = 0.03] and A1AT [OR 1.02 (95%CI 1.01-1.03), p = 0.003] and lower cholesterol levels [OR 0.98 (95%CI 0.97-0.99), p = 0.009] than COPD controls. We developed a risk score variable combining neutrophils, A1AT and cholesterol, achieving a sensitivity of 80%, a negative predictive value of 90.7% and an area under the curve of 0.78 (95%CI 0.71-0.86).
COPD patients who also have LC have higher levels of neutrophils and A1AT and lower of cholesterol. These parameters could be potentially predicting biomarkers of LC in COPD patients.
慢性阻塞性肺疾病(COPD)与肺癌(LC)的发展之间存在关系。本研究旨在分析几种血液标志物,并比较仅患有 COPD 和 LC+COPD 的患者的浓度。
病例对照研究,病例为合并 LC 和 COPD 的患者,对照组为仅患有 COPD 的患者和仅患有 LC 的患者。我们还纳入了具有描述性目的的 LC 患者。在两组患者中,均进行了外周血 TNF-α、IL-6、IL-8、白细胞总数、淋巴细胞和中性粒细胞计数、中性粒细胞与淋巴细胞比值、血小板总数、血小板平均体积、血小板与淋巴细胞比值、α1-抗胰蛋白酶(A1AT)、IgE、C 反应蛋白、纤维蛋白原、胆固醇和胆红素分析。我们对这些标志物进行了单变量和多变量分析,并开发了风险评分变量,通过 ROC 曲线评估其性能。
我们纳入了 280 名患者,109 例(LC+COPD),83 例对照(COPD)和 88 例无 COPD 的 LC。在性别、年龄、BMI、吸烟、职业暴露、肺功能、GOLD 分期或合并症方面,两组的分布无差异。LC+COPD 患者的中性粒细胞[比值比(OR)1.00(95%置信区间 1.00-1.00),p=0.03]和 A1AT[OR 1.02(95%置信区间 1.01-1.03),p=0.003]水平显著升高,胆固醇水平[OR 0.98(95%置信区间 0.97-0.99),p=0.009]显著降低,与 COPD 对照组相比。我们开发了一个风险评分变量,结合了中性粒细胞、A1AT 和胆固醇,达到了 80%的敏感性、90.7%的阴性预测值和 0.78(95%置信区间 0.71-0.86)的曲线下面积。
同时患有 COPD 和 LC 的患者中性粒细胞和 A1AT 水平较高,胆固醇水平较低。这些参数可能是 COPD 患者中潜在的 LC 预测生物标志物。